Cutting edge: constitutive B cell receptor signaling is critical for basal growth of B lymphoma
- PMID: 16670274
- DOI: 10.4049/jimmunol.176.10.5715
Cutting edge: constitutive B cell receptor signaling is critical for basal growth of B lymphoma
Erratum in
- J Immunol. 2006 Jun 15;176(12):7789
Abstract
B lymphomas account for the majority of the lymphoma cases. BCR expression appears to be important for B lymphoma because most oncogenes are translocated to nonrearranged Ig loci and because all of the variants that arise in anti-idiotypic Ab-treated lymphoma patients remain BCR positive. Based on this and the fact that BCR is required for mature B cell survival, we tested the requirement for continued expression of BCR for the growth and survival of B lymphoma cells. Using Igalpha or Igbeta-specific small interfering RNA (siRNA) to inhibit BCR expression, we demonstrate for the first time that constitutive signaling by BCR is critical for survival and proliferation of both murine and human B lymphoma cells. The BCR signals in lymphoma appear to be mediated by Syk, as it is constitutively active in a variety of B lymphoma cells. Blocking Syk activity by selective inhibitors suppresses growth of several murine and human B lymphomas.
Similar articles
-
Activation of the Syk tyrosine kinase is insufficient for downstream signal transduction in B lymphocytes.BMC Immunol. 2002 Dec 6;3:16. doi: 10.1186/1471-2172-3-16. Epub 2002 Dec 6. BMC Immunol. 2002. PMID: 12470302 Free PMC article.
-
Spleen tyrosine kinase (Syk), a novel target of curcumin, is required for B lymphoma growth.J Immunol. 2007 Jan 1;178(1):111-21. doi: 10.4049/jimmunol.178.1.111. J Immunol. 2007. PMID: 17182546
-
SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma.Blood. 2008 Feb 15;111(4):2230-7. doi: 10.1182/blood-2007-07-100115. Epub 2007 Nov 15. Blood. 2008. PMID: 18006696 Free PMC article.
-
Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas.Expert Rev Anticancer Ther. 2010 Sep;10(9):1407-18. doi: 10.1586/era.10.112. Expert Rev Anticancer Ther. 2010. PMID: 20836676 Review.
-
New insights into pre-BCR and BCR signalling with relevance to B cell malignancies.Nat Rev Immunol. 2013 Aug;13(8):578-91. doi: 10.1038/nri3487. Nat Rev Immunol. 2013. PMID: 23883968 Review.
Cited by
-
Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial.Lancet Oncol. 2014 Jan;15(1):48-58. doi: 10.1016/S1470-2045(13)70513-8. Epub 2013 Dec 10. Lancet Oncol. 2014. PMID: 24332241 Free PMC article. Clinical Trial.
-
T and NK cell lymphoma cell lines do not rely on ZAP-70 for survival.PLoS One. 2022 Jan 25;17(1):e0261469. doi: 10.1371/journal.pone.0261469. eCollection 2022. PLoS One. 2022. PMID: 35077445 Free PMC article.
-
Population Pharmacokinetics and Exposure Response Assessment of CC-292, a Potent BTK Inhibitor, in Patients With Chronic Lymphocytic Leukemia.J Clin Pharmacol. 2017 Oct;57(10):1279-1289. doi: 10.1002/jcph.923. Epub 2017 May 19. J Clin Pharmacol. 2017. PMID: 28543084 Free PMC article. Clinical Trial.
-
The SYK tyrosine kinase: a crucial player in diverse biological functions.Nat Rev Immunol. 2010 Jun;10(6):387-402. doi: 10.1038/nri2765. Nat Rev Immunol. 2010. PMID: 20467426 Free PMC article. Review.
-
B cell activator PAX5 promotes lymphomagenesis through stimulation of B cell receptor signaling.J Clin Invest. 2007 Sep;117(9):2602-10. doi: 10.1172/JCI30842. J Clin Invest. 2007. PMID: 17717600 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous